menu
    • menu
    [{"orgOrder":0,"company":"Erkim","sponsor":"MEDICE Health Family","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"TURKEY","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Erkim \/ MEDICE Health Family","highestDevelopmentStatusID":"15","companyTruncated":"Erkim \/ MEDICE Health Family"},{"orgOrder":0,"company":"Erkim","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"TURKEY","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Erkim \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Erkim \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Erkim","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TURKEY","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Erkim \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Erkim \/ Quoin Pharmaceuticals"},{"orgOrder":0,"company":"Erkim","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TURKEY","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Erkim \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Erkim \/ Quoin Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Erkim

    Menu

    Erkim

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Erkim

    Turkey arrow
    AAN
    Not Confirmed

    Erkim

    Turkey arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vadadustat

    Therapeutic Area : Nephrology

    Study Phase : Approved FDF

    Sponsor : MEDICE Health Family

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Er-Kim Announces Distribution Agreement with MEDICE for Vafseo® in Europe

    Details : Under the agreement, Er-Kim partner with the MEDICE to commercialize the Vafseo (vadadustat). It is being indicated for the treatment of of symptomatic anaemia associated with CKD in adults.

    Product Name : Vafseo

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    January 14, 2025

    Lead Product(s) : Vadadustat

    Therapeutic Area : Nephrology

    Highest Development Status : Approved FDF

    Sponsor : MEDICE Health Family

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Erkim

    Turkey arrow
    AAN
    Not Confirmed

    Erkim

    Turkey arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Berotralstat HCl

    Therapeutic Area : Genetic Disease

    Study Phase : Approved FDF

    Sponsor : BioCryst Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey

    Details : Under the collaboration, Er-Kim Pharmaceuticals will commercialize Orladeyo (berotralstat), the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older, in Tur...

    Product Name : Orladeyo

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    July 19, 2023

    Lead Product(s) : Berotralstat HCl

    Therapeutic Area : Genetic Disease

    Highest Development Status : Approved FDF

    Sponsor : BioCryst Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Erkim

    Turkey arrow
    AAN
    Not Confirmed

    Erkim

    Turkey arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : QRX003

    Therapeutic Area : Rare Diseases and Disorders

    Study Phase : Preclinical

    Sponsor : Quoin Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Nethe...

    Details : Under the terms of the revenue sharing agreement, ER-Kim gains exclusive rights to commercialize QRX003 in fifteen countries throughout the CEE. Quoin will be the exclusive supplier of QRX003 to ER-Kim.

    Product Name : QRX003

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    October 02, 2022

    Lead Product(s) : QRX003

    Therapeutic Area : Rare Diseases and Disorders

    Highest Development Status : Preclinical

    Sponsor : Quoin Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Erkim

    Turkey arrow
    AAN
    Not Confirmed

    Erkim

    Turkey arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : QRX003

    Therapeutic Area : Rare Diseases and Disorders

    Study Phase : Preclinical

    Sponsor : Quoin Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Net...

    Details : Under the terms of the revenue sharing agreement, which was initially announced earlier in February 2022, ER-Kim gains exclusive rights to commercialize QRX003 in six additional countries. Quoin will be the exclusive supplier of QRX003 to ER-Kim.

    Product Name : QRX003

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    January 03, 2022

    Lead Product(s) : QRX003

    Therapeutic Area : Rare Diseases and Disorders

    Highest Development Status : Preclinical

    Sponsor : Quoin Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth